Joharatnam-Hogan, Nalinie
Hatem, Duaa
Cafferty, Fay H.
Petrucci, Giovanna
Cameron, David A. http://orcid.org/0000-0002-2717-7979
Ring, Alistair http://orcid.org/0000-0003-1230-2973
Kynaston, Howard G.
Gilbert, Duncan C.
Wilson, Richard H. http://orcid.org/0000-0001-8018-7730
Hubner, Richard A.
Swinson, Daniel E. B. http://orcid.org/0000-0002-6186-5759
Cleary, Siobhan http://orcid.org/0000-0003-1741-478X
Robbins, Alex
MacKenzie, Mairead
Scott-Brown, Martin W. G.
Sothi, Sharmila
Dawson, Lesley K.
Capaldi, Lisa M.
Churn, Mark
Cunningham, David http://orcid.org/0000-0001-5158-1069
Khoo, Vincent
Armstrong, Anne C.
Ainsworth, Nicola L.
Horan, Gail
Wheatley, Duncan A.
Mullen, Russell
Lofts, Fiona J. http://orcid.org/0000-0002-6268-6015
Walther, Axel
Herbertson, Rebecca A.
Eaton, John D.
O’Callaghan, Ann
Eichholz, Andrew
Kagzi, Mohammed M.
Patterson, Daniel M.
Narahari, Krishna
Bradbury, Jennifer
Stokes, Zuzana
Rizvi, Azhar J.
Walker, Georgina A.
Kunene, Victoria L.
Srihari, Narayanan
Gentry-Maharaj, Aleksandra
Meade, Angela http://orcid.org/0000-0002-7962-964X
Patrono, Carlo
Rocca, Bianca
Langley, Ruth E. http://orcid.org/0000-0002-9706-016X
Funding for this research was provided by:
Cancer Research UK (C471/A19252, C569/A24991, C471/A15015)
DH | National Institute for Health Research (12/01/38)
RCUK | Medical Research Council (MC_UU_00004/02, MC_UU_12023/28)
Article History
Received: 31 October 2022
Revised: 9 May 2023
Accepted: 5 June 2023
First Online: 7 July 2023
Competing interests
: DC reports grants from MedImmune/ AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, NIHR EME, Leap, Roche and ownership interest and advisory role to OVIBIO. VK reports honoraria for speakers’ bureaus, personal fees and non-financial support from Accuray, Astellas, Bayer, Boston Scientific, and Janssen. DW reports sponsorship from Roche, AstraZeneca, Novartis, Pfizer for ad boards and travel fees from Roche. AW reports consulting fees from GlaxoSmithKline, Clovis, MSD and conference attendance from GlaxoSmithKline. VK reports honorarium from Servier, Roche, Amgen and Clovis Oncology pharmaceutical companies for presentation, educational meeting support, and article write-up. AG-M is a co-investigator on studies exploring novel biomarkers in ovarian cancer, funded by Micronoma and iLoF, with the research funding awarded to UCL. CP reports personal fees from Acticor Biotech, Amgen, Bayer, Eli Lilly, Tremeau, and Zambon; institutional grants from AIFA (Italian Medicines Agency), Bayer, Cancer Research UK, and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation. BR reports speaker fees from Swedish Orphan Biovitrum AB, a grant for an investigator-initiated trial from Bayer AG and consulting fees from Aboca. RL reports grant funding for the Add-Aspirin trial and the AsCaP collaboration, and honorarium from the Aspirin Foundation supported by Bayer. The remaining authors declare no competing interests.
: The trial protocol, including the platelet activation sub-study, was approved by South Central-Oxford C research ethics committee (Ref: 14/SC/0171) and by local research and development departments at all centres. Participants provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.